WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Newsletter: June 2021
WuXi Biologics Completed Three Acquisitions to Enhance its Global Network
Facilities and Operations
WuXi Biologics and WuXi STA Jointly Established WuXi XDC to Provide Fully Integrated Bioconjugate CDMO Services Read More
WuXi Biologics Receives GMP Conformity Assessment from the Singapore Health Sciences Authority (HSA) Read More
WuXi Biologics Successfully Completed Pre-License Inspection and Routine GMP Inspection by U.S. FDA Read More
WuXi Biologics Receives GMP Certification from Brazil’s ANVISA Read More
The World’s Largest 36,000L Biomanufacturing Line Using Single-use Bioreactors Launches GMP Operation at WuXi Biologics Read More
Resources
The Challenge of Staying Current with Regulatory Changes – How one company is providing a solution. View this Podcast
Antibody Drug Conjugates (ADC) Drug Development and Manufacturing Trends, Challenges and Solutions (Webinar)
Expediting Biologics Drug Development: Strategies to Accelerate Preclinical Development Timelines (Webinar)
Applications and Impact of CRISPR/Cas9 in Bioprocessing (Podcast)
Continuous Biomanufacturing Implementation – Using an Intensified and Integrated Bioprocess Platform (White Paper)
Reducing Fill Risk in Drug Product Manufacture Utilizing New State-of-the-Art Systems and Platforms (Podcast)
Scale-Out Biomanufacturing – A Paradigm Change to Scale-Up (White Paper)
Partner News
WuXi XDC and LegoChem Biosciences Signed Memorandum of Understanding for the Development and Manufacturing of Antibody-drug Conjugates Read More
WuXi Biologics Congratulates Emergency Use Authorization of Sotrovimab for the treatment of COVID-19 Read More
Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline Read More
WuXi Biologics Congratulates Vir Biotechnology on Positive Data from Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Read More
WuXi Biologics, WuXi STA and Antengene Announce Collaboration to Advance Antibody-Drug Conjugate Candidate into Clinical Stage Read More
Awards
WuXi Biologics Named China’s Most Attractive Employer Read More
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?